GlassScriptPhysician profile
Anne M Ambs
NPI 1285150441
$15,522.67
in general payments reported to CMS, 2019-2025
41 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,384 · 2022: $2,772 · 2023: $2,882 · 2024: $3,684 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $112 · Consulting Fee: $37.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,217.51 |
| Education | $111.98 |
| Consulting Fee | $37.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,248.07 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $2,093.46 | 2021-2025 | Dupixent |
| Amgen INC. | $1,368.38 | 2021-2025 | Tezspire |
| Genzyme Corporation | $1,324.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,012.58 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $658.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $571.50 | 2021-2025 | Takhzyro, Glassia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $470.37 | 2022-2025 | |
| Optinose US, INC. | $402.94 | 2021-2025 | |
| Pfizer INC. | $400.96 | 2021-2025 | |
| Incyte Corporation | $270.04 | 2022-2025 | Opzelura |
| Kaleo, INC. | $253.22 | 2021-2024 | Auvi-Q |
| Csl Behring | $252.43 | 2022-2025 | Haegarda, Andembry, Hizentra |
| Teva Pharmaceuticals USA, INC. | $235.37 | 2021-2022 | |
| Lilly USA, LLC | $210.79 | 2024-2025 | Ebglyss |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Ambs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.